Canine Leptospirosis: Clinical Diagnosis, Serovar Prevalence, and One Health Implications

Abstract

Canine leptospirosis represents a globally distributed zoonotic bacterial disease caused by pathogenic spirochetes of the genus Leptospira. The disease manifests with heterogeneous clinical presentations ranging from subclinical infection to acute kidney injury, hepatic dysfunction, and pulmonary hemorrhage syndrome. Accurate diagnosis requires integration of serological testing, primarily the microscopic agglutination test (MAT), with molecular detection methods such as polymerase chain reaction (PCR). Serovar prevalence exhibits distinct geographic variation influenced by reservoir host ecology and environmental factors. This review synthesizes current knowledge on pathogenesis, diagnostic algorithms, regional serovar distribution, therapeutic interventions, vaccination strategies, and the One Health dimensions of canine leptospirosis.

1. Etiology and Pathogenesis

1.1 Taxonomy and Classification

The genus Leptospira comprises spirochetal bacteria classified into pathogenic, intermediate, and saprophytic clades based on phylogenetic analysis of the 16S rRNA gene and whole-genome sequencing. Pathogenic species include Leptospira interrogans, Leptospira kirschneri, Leptospira noguchii, Leptospira santarosai, Leptospira weilii, Leptospira alexanderi, Leptospira kmetyi, and Leptospira alstonii. Serological classification identifies over 250 serovars grouped into serogroups based on antigenic relatedness of the lipopolysaccharide (LPS) component. The LPS structure determines serovar specificity and represents the primary target of protective immunity.

1.2 Virulence Mechanisms

Pathogenic Leptospira species possess specialized virulence factors facilitating host invasion, immune evasion, and tissue colonization. Outer membrane proteins (OMPs) such as LipL32, LipL41, and Loa22 mediate adhesion to extracellular matrix components including fibronectin, laminin, and collagen. The Loa22 protein, a lipoprotein expressed during mammalian infection, has been evaluated as a diagnostic antigen in recombinant formats including gold nanoparticle-based lateral flow assays [1]. Motility mediated by periplasmic flagella enables tissue penetration and dissemination. The cGAS-STING pathway mediates type I interferon responses that restrict renal colonization in murine models, highlighting innate immune mechanisms controlling bacterial persistence [2].

1.3 Host-Pathogen Interactions

Following mucosal or percutaneous entry, leptospires disseminate hematogenously to target organs including kidneys, liver, lungs, and reproductive tract. Renal tubular colonization establishes the carrier state with intermittent urinary shedding. Hepatic involvement produces centrilobular necrosis and cholestasis. Pulmonary pathology manifests as alveolar hemorrhage, interstitial pneumonia, and vascular leakage. Serial imaging studies in naturally infected dogs document progressive pulmonary changes including ground-glass opacities, consolidation, and pleural effusion correlating with clinical severity [3]. Serum sialic acid concentrations increase during acute infection, reflecting systemic inflammatory response and acute-phase reactant dynamics [4].

2. Clinical Presentation

2.1 Acute Disease Manifestations

Acute leptospirosis in dogs typically presents with nonspecific signs including lethargy, anorexia, vomiting, diarrhea, and fever. Organ-specific manifestations include:

Renal: Acute kidney injury (AKI) characterized by azotemia, oliguria or anuria, proteinuria, glucosuria, and isosthenuria. Histopathology reveals tubular necrosis, interstitial nephritis, and regenerative changes.

Hepatic: Icterus, elevated hepatocellular leakage enzymes (ALT, AST), increased bilirubin, and coagulopathy secondary to impaired synthetic function.

Pulmonary: Tachypnea, dyspnea, cough, hemoptysis, and radiographic evidence of alveolar hemorrhage. Pulmonary hemorrhage syndrome carries high mortality despite aggressive supportive care.

Musculoskeletal: Myalgia, reluctance to move, and stiffness.

2.2 Subclinical and Chronic Infection

Subclinical infections contribute to maintenance of the pathogen in canine populations. Chronically infected dogs may shed leptospires intermittently in urine for months to years, serving as reservoirs for environmental contamination and transmission to contact animals [5]. Serological surveys in endemic regions detect high seroprevalence in apparently healthy dogs, indicating frequent exposure without overt disease.

2.3 Clinicopathological Findings

3. Diagnostic Approaches

3.1 Microscopic Agglutination Test (MAT)

The MAT remains the reference standard for serological diagnosis and serovar identification. The assay measures agglutinating antibodies against a panel of live Leptospira antigens representing locally relevant serovars. A fourfold rise in titer between acute and convalescent samples collected 2-4 weeks apart confirms recent infection. Single titers ≥1:800 in unvaccinated dogs with compatible clinical signs support presumptive diagnosis. Vaccination induces cross-reactive antibodies complicating interpretation. The MAT requires maintenance of live antigen cultures, specialized dark-field microscopy, and trained personnel.

3.2 Molecular Detection

PCR assays targeting conserved genes (e.g., lipL32, 16S rRNA, secY, gyrB) enable direct pathogen detection in blood, urine, and tissues. Blood PCR sensitivity peaks during the leptospiremic phase (first 7-10 days post-infection). Urine PCR detects renal shedding but may yield false negatives during intermittent excretion. Quantitative PCR provides bacterial load estimation correlating with disease severity. Molecular characterization of outbreak strains facilitates epidemiological tracking and source attribution [6, 7].

3.3 Emerging Serological Assays

Recombinant antigen-based assays offer alternatives to whole-cell MAT. A lateral flow assay utilizing recombinant Loa22 conjugated to gold nanoparticles demonstrated diagnostic sensitivity and specificity for canine and bovine leptospirosis [1]. Enzyme-linked immunosorbent assays (ELISAs) targeting LipL32 or conserved epitopes provide high-throughput screening capability. Point-of-care immunochromatographic tests enable rapid field deployment but require validation against reference standards.

3.4 Diagnostic Algorithm

flowchart TD
    A[Clinical Suspicion: Compatible Signs + Exposure Risk], > B{Acute Phase ≤10 days?}
    B, >|Yes| C[Blood PCR + Acute MAT]
    B, >|No| D[Urine PCR + Acute MAT]
    C, > E{PCR Positive?}
    D, > E
    E, >|Yes| F[Confirmed Diagnosis]
    E, >|No| G[Convalescent MAT at 2-4 weeks]
    G, > H{Fourfold Titer Rise?}
    H, >|Yes| F
    H, >|No| I[Consider Alternative Diagnoses]
    F, > J[Treatment Initiation + Public Health Notification]
    I, > K[Monitor Clinical Course]
    K, > G

3.5 Differential Diagnosis

Differential considerations include acute kidney injury from other etiologies (toxins, ischemia, immune-mediated), infectious hepatitis (canine adenovirus type 1), immune-mediated hemolytic anemia, thrombocytopenia, pancreatitis, and other zoonotic bacterial infections. Co-infections with vector-borne pathogens may occur in endemic regions.

4. Serovar Prevalence and Geographic Distribution

4.1 Global Serovar Ecology

Serovar distribution reflects reservoir host adaptation and environmental persistence. Maintenance hosts include rodents (serovars Icterohaemorrhagiae, Copenhageni, Bratislava), livestock (Hardjo, Pomona), and wildlife (Grippotyphosa, Canicola). Dogs serve as maintenance hosts for serovar Canicola and incidental hosts for other serovars. Geographic variation necessitates region-specific MAT panels.

4.2 Regional Epidemiology

North America: Serovars Pomona, Grippotyphosa, Bratislava, and Icterohaemorrhagiae predominate. An outbreak investigation in Los Angeles County identified L. interrogans serovar Canicola as the causative agent with evidence of dog-to-dog transmission [6].

South America: High diversity includes serovars Canicola, Icterohaemorrhagiae, Copenhageni, Australis, and Pyrogenes. Serological surveys in indigenous communities in Brazil revealed exposure to multiple Leptospira species alongside other zoonotic pathogens [8]. Molecular surveillance in northern Colombia detected L. interrogans and L. kirschneri in domestic dogs [7].

Asia: Serovars Autumnalis, Hebdomadis, Javanica, and Pyrogenes are frequently reported. Systematic review and meta-analysis of Chinese data identified L. interrogans as the dominant species with serovars Icterohaemorrhagiae, Canicola, and Sejroe prevalent in canine populations [9, 10]. Genomic comparison of Japanese isolates from humans, dogs, and wildlife revealed clonal relationships supporting cross-species transmission [11]. Pathogenic Leptospira species were identified in dogs and cats during neutering programs in Thailand [12].

Europe: Serovars Icterohaemorrhagiae, Copenhageni, Bratislava, and Grippotyphosa are commonly reported. Risk assessment studies in Australia quantified transmission probability among contact dogs [5].

4.3 Environmental Drivers

Meteorological factors including rainfall, temperature, and flooding events correlate with leptospirosis incidence in domestic animal populations [13]. Soil moisture, pH, and standing water facilitate environmental survival. Urbanization alters reservoir host communities and human-animal interfaces influencing transmission dynamics.

5. Treatment Protocols

5.1 Antimicrobial Therapy

Doxycycline: 5 mg/kg PO q12h for 14 days represents the treatment of choice for elimination of renal carriage. Intravenous formulation enables administration in vomiting patients.

Penicillin derivatives: Ampicillin (20 mg/kg IV q6h) or penicillin G (20,000-40,000 IU/kg IV q6h) effectively terminate leptospiremia but do not clear renal colonization. Used for initial stabilization followed by doxycycline.

Ceftriaxone: 20 mg/kg IV q24h provides alternative parenteral option with extended half-life.

5.2 Supportive Care

Fluid therapy: Balanced crystalloids with potassium supplementation for AKI management. Avoid fluid overload in oliguric patients.

Renal replacement therapy: Hemodialysis or peritoneal dialysis indicated for severe AKI refractory to medical management.

Nutritional support: Enteral feeding preferred; parenteral nutrition if gastrointestinal dysfunction precludes enteral route.

Gastroprotectants: Antiemetics, antacids, and sucralfate for gastrointestinal mucosal protection.

Blood products: Fresh frozen plasma or packed red blood cells for coagulopathy or severe anemia.

5.3 Monitoring Parameters

Serial assessment of renal values, electrolytes, acid-base status, coagulation profile, and urine output guides therapeutic adjustments. Pulmonary monitoring includes thoracic radiography, pulse oximetry, and arterial blood gas analysis in respiratory compromise.

6. Vaccination Strategies

6.1 Vaccine Types

Inactivated bacterins: Whole-cell killed vaccines containing 2-4 serovars (typically Canicola, Icterohaemorrhagiae, Grippotyphosa, Pomona). Induce primarily humoral immunity against LPS.

Subunit vaccines: Recombinant OMP vaccines under investigation to broaden serovar coverage and reduce reactogenicity.

6.2 Immunogenicity and Duration

Protective immunity correlates with agglutinating antibody titers. Annual revaccination recommended based on challenge studies demonstrating waning protection. Vaccination reduces clinical disease severity and renal shedding but may not prevent infection entirely.

6.3 Vaccination Protocols

Primary series: Two doses 2-4 weeks apart starting at 8-12 weeks of age. Booster at 1 year then annually. High-risk dogs (hunting, field trial, endemic area residence) may benefit from semi-annual boosters.

6.4 Limitations

Serovar-specific protection limits cross-protection. Regional serovar mismatch reduces vaccine efficacy. MAT interpretation complicated by vaccine-induced titers. Adverse reactions include transient lethargy, local swelling, and rare hypersensitivity events.

7. One Health Implications

7.1 Zoonotic Transmission

Dogs serve as sentinel species and potential amplifiers of human leptospirosis. Direct transmission via infected urine occurs through mucosal contact or contaminated environments. Occupational risk affects veterinary personnel, shelter workers, and laboratory staff. Standard precautions including gloves, face protection, and disinfection protocols mitigate occupational exposure.

7.2 Environmental Contamination

Urinary shedding contaminates soil, surface water, and food sources. Survival in moist environments extends transmission windows. Rodent control, sanitation, and drainage management reduce environmental burden.

7.3 Surveillance Integration

Integrated human-animal surveillance systems enhance outbreak detection. Genomic epidemiology linking canine, human, wildlife, and livestock isolates elucidates transmission networks [14, 11]. The One Health approach coordinates veterinary, medical, and environmental health sectors for comprehensive control strategies.

7.4 Public Health Reporting

Canine leptospirosis is reportable in many jurisdictions. Timely notification enables contact tracing, environmental assessment, and human case investigation. Veterinary diagnostic laboratories play critical roles in data generation and sharing.

8. Prevention and Control

8.1 Kennel and Shelter Management

Quarantine protocols for new admissions, rodent exclusion, drainage maintenance, and disinfection with quaternary ammonium compounds or hypochlorites reduce transmission risk. Isolation of confirmed cases with dedicated equipment and personnel prevents nosocomial spread.

8.2 Owner Education

Risk communication regarding exposure routes (standing water, wildlife contact, rodent infestation), clinical sign recognition, and vaccination benefits improves compliance. Zoonotic risk awareness promotes hygiene practices.

8.3 Wildlife and Reservoir Management

Population management of maintenance hosts, habitat modification, and vaccination of livestock in endemic areas reduce spillover pressure. Oral vaccine delivery systems for wildlife reservoirs remain experimental.

9. Future Directions

9.1 Diagnostic Innovation

Multiplex PCR panels differentiating pathogenic Leptospira species and serovars will enhance diagnostic resolution. Next-generation sequencing applied directly to clinical specimens enables strain typing without culture. Point-of-care molecular platforms may decentralize testing capacity.

9.2 Vaccine Development

Reverse vaccinology approaches identifying conserved protective antigens across serovars promise broad-spectrum vaccines. Viral vector and mRNA platforms may induce both humoral and cell-mediated immunity. Mucosal vaccination strategies targeting renal colonization could interrupt transmission cycles.

9.3 Computational Epidemiology

Machine learning models integrating climatic, ecological, and demographic data predict spatiotemporal risk patterns. Genomic surveillance networks with real-time data sharing facilitate early detection of emerging strains and antimicrobial resistance.

9.4 Host-Directed Therapies

Modulation of innate immune pathways (e.g., cGAS-STING) may enhance bacterial clearance while limiting immunopathology. Adjunctive therapies targeting vascular leakage and coagulation dysregulation could improve outcomes in severe pulmonary hemorrhage.

10. Conclusion

Canine leptospirosis remains a significant veterinary and public health challenge requiring integrated diagnostic, therapeutic, and preventive approaches. Advances in molecular diagnostics, genomic epidemiology, and vaccine technology continue to refine management strategies. The One Health framework provides essential coordination across human, animal, and environmental health sectors to mitigate the impact of this re-emerging zoonosis. Continued surveillance, research investment, and interdisciplinary collaboration are imperative for effective control.

References

[1] Gautam H, Kumar BVS, Singh S et al. Evaluation of a recombinant Loa22-gold nanoparticle based lateral flow assay for the serodiagnosis of leptospirosis in canine and bovine. Arch Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41524783/

[2] Gupta S, Matsunaga J, Ratitong B et al. cGAS-STING dependent type I IFN reduces Leptospira interrogans renal colonization in mice. PLoS Pathog. 2026. https://pubmed.ncbi.nlm.nih.gov/41499635/

[3] Bringold C, Schweighauser A, Walther S et al. Serial evaluation of clinical, functional, and structural pulmonary changes in 10 dogs with leptospirosis. J Vet Intern Med. 2026. https://pubmed.ncbi.nlm.nih.gov/42224492/

[4] Yaghoobpour T, Faraji M, Nazifi S. Serum Sialic Acid as a Biomarker of Inflammation and Infection: Insights From Veterinary Medicine. Vet Med Int. 2026. https://pubmed.ncbi.nlm.nih.gov/42148179/

[5] Skinner VJ, Ward MP, Griebsch C. Risk of infection in dogs in contact with clinical canine leptospirosis cases. Aust Vet J. 2026. https://pubmed.ncbi.nlm.nih.gov/41814781/

[6] Randolph MW, Nally JE, Yoshimoto SK et al. Clinical and molecular characterization of an outbreak of leptospirosis in dogs from Los Angeles County, California, USA, 2021. J Clin Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/42189535/

[7] Beltrán-Sánchez CA, Bettin AC, Castellanos-Romero K et al. Molecular surveillance of Leptospira infection in domestic dogs in Soledad, Northern Colombia. Vet Res Commun. 2026. https://pubmed.ncbi.nlm.nih.gov/41557245/

[8] Galvão CMMQ, Leite DPSBM, Oliveira PRF et al. First serological investigation of Toxoplasma gondii, Neospora caninum, Leishmania infantum and Leptospira spp. in dogs from a Fulni-ô Indigenous community in Pernambuco, Brazil: a One Health perspective. Braz J Biol. 2026. https://pubmed.ncbi.nlm.nih.gov/41849483/

[9] Wei W, Jiao D, Dong X et al. Epidemiology and associated factors of human and canine leptospirosis in China: a systematic review and meta-analysis. Prev Vet Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41864068/

[10] Ding Y, Zhang S, Zhang W et al. Seroprevalence and Molecular Epidemiology of Leptospira spp. Infecting Dogs in the Yangtze River Region of China. Transbound Emerg Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/41383393/

[11] Kakita T, Takabe K, Morita M et al. Genomic comparison of Leptospira interrogans isolated from humans, dogs, and wild and feral animals in Japan. Int J Med Microbiol. 2026. https://pubmed.ncbi.nlm.nih.gov/41579465/

[12] Thongdee M, Chaiwattanarungruengpaisan S, Paungpin W et al. Pathogenic Leptospira species identified in dogs and cats during neutering in Thailand. PLoS Negl Trop Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41637464/

[13] Hobson SJ, Zai B, Vyn CM et al. Impacts of meteorological factors on zoonotic infections in domestic cat and dog populations: A scoping review of international evidence. One Health. 2026. https://pubmed.ncbi.nlm.nih.gov/42211529/

[14] Patiño-Gómez S, Naranjo-Vargas LF, Aguirre-Acevedo DC et al. Epidemiological study of leptospiral interaction in bovine farms in rural areas of Colombia: A One Health approach. PLoS Negl Trop Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42090421/

[15] Decoster C, Lefère L, Raes E et al. Equine leptospiral pulmonary haemorrhage syndrome: An atypical manifestation of equine leptospirosis. Equine Vet J. 2026. https://pubmed.ncbi.nlm.nih.gov/41451997/